Pre-existing antibody patterns helped identify people with weaker vaccine responses. Digest
Having a weakened or medically suppressed immune system can signal a higher risk of weak vaccine responses, but it cannot reveal exactly how one person will respond. Researchers tested whether the antibodies already carried from earlier immune encounters could provide a more individualized signal.
Researchers analyzed blood samples from more than 4,000 healthy and immunosuppressed participants before and after COVID-19 vaccination. They measured antibodies to 185 targets from viruses, bacteria, and the body's own proteins and compared them with each person's vaccine-induced antibody response. AI models used 98 commonly detected antibodies that did not target SARS-CoV-2 or HIV, along with age, sex, race, and participant group information, to separate stronger from weaker booster responders.
- Pre-existing antibodies to common microbes distinguished strong from weak COVID-19 vaccine responders across several clinical groups.
- The AI model applied across all groups captured part of that signal, identifying about six in ten weak responders while correctly classifying eight in ten stronger responders.
- The signature did not work equally well in every patient group, performing poorly in autoimmune and transplant patients.
Antibody levels are shaped by what the immune system has encountered and by how effectively its antibody-producing arm builds and maintains those responses. Stable antibodies to common microbes can therefore act as indirect measures of the health of this part of the immune system. A broad pattern of stronger past responses may reveal a system that is also prepared to mount a stronger response to a vaccine. However, the study only tested the prediction of antibody levels, not infection outcomes or other immune-cell responses.
You just missed this in your inbox
Every other week our Premium Members received this exact study plus Rhonda's practical commentary and 8+ other hand-picked papers.
The AI model was not equally accurate in every patient group, yet its shared antibody features exposed a biological pattern that broad patient group labels alone missed. Existing antibodies may therefore function as a window into the health of the antibody-producing immune system, not merely as evidence of past infection.